AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03868631 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein supplement
Description: 26 g soy protein isolate (contains 2 g leucine) was consumed daily by the other intervention group.
Study NCT02707276 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
Study NCT02707276 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low Field Magnetic Stimulation
Description: The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment by producing mimicking sounds.
Study NCT03702816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GE180 PET Scan
Description: GE180 PET Scan
Study NCT01181830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: magnesium pidolate
Description: administration of 8.1 mmol bid of magnesium pidolate
Study NCT01181830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administration of 8.1 mmol bid of placebo
Study NCT00089973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ispinesib
Description: Given intravenously at a dose of 18 milligram (mg)/ meter square (m\^2).
Study NCT01223027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
Study NCT04216719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OCM-RISE
Description: OCM RISE will comprise four phases (Exploratory, Preparation, Implementation, and Sustainment). During Exploration, staff will conduct readiness surveys, interviews and system mapping exercises to assess county context. In the Preparation Phase, the needs assessment data will inform county-specific action plans. Guided facilitation during this phase includes court development planning, practice/process improvement strategies, and training on data-driven decision-making to help IACTs operationalize the 10 OCM guidelines, assess performance, and fit the guideline to the local context. In the Implementation Phase, counties will roll out the OCM for 18 months with data feedback, support, and facilitation. Each IACT will receive reports on the performance of its OCM and complete two plan-do-study-act cycles. In the Sustainment Phase, implementation and feedback reports will continue for 6-18 months, but without other external facilitation.
Study NCT04334525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice architecture + repeated exposure
Description: Participants will receive placemats promoting healthier featured kids' meals and the opportunity to redeem their kids' meal token for a toy instead of dessert. Families will also receive a frequent diner card, which after purchasing one of the featured healthier kids' meals across 6 occasions, makes them eligible for a free kids' meal of their choice during a predetermined redemption period.
Study NCT02414672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareSTEPS
Description: Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
Study NCT01223027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
Study NCT00691756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold blood renal perfusion
Description: Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
Study NCT00691756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid renal perfusion
Description: Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
Study NCT02287220 — intervention group
Intervention type: DEVICE
Intervention: Non-Contact Oximetry
Description: Video Record subject when subjected to small amounts of near infrared light
Study NCT01420614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral approach
Description: diagnostic and interventional procedures by femoral artery access
Study NCT01420614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial approach
Description: diagnostic and interventional procedures by radial artery access
Study NCT02223169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg albumin-derived peptide
Description: Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
Study NCT02223169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Egg albumin-derived peptide
Description: Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
Study NCT04158427 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Faecal transplantation
Description: Faecal transplantation from a healthy donor via colonoscopy
Study NCT04158427 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo faecal transplantation
Description: Placebo faecal transplantation containing patient's own feces via colonoscopy
Study NCT03448692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06730512
Description: Subjects in cohort 1 will receive Dose 1 Intravenous infusion (IV). Subjects in cohort 2 will receive Dose 2 IV. Subjects in cohort 3 will receive Dose 3 IV infusion.
Study NCT02591849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon-like peptide-1 (GLP-1)
Study NCT02591849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Study NCT04854642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ladarixin
Description: A single oral dose of 400 mg of ladarixin (two 200 mg capsules) was administered to healthy male and female volunteers under fed (Test treatment) and fasting (Reference treatment) conditions in two consecutive study periods, according to a two-way crossover design, with a wash-out interval of at least 14 days between the two administrations.
Study NCT03320603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Expert eCRF
Description: An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
Study NCT03320603 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Prothrombin Complex Concentrate
Description: Prothrombin Complex Concentrate given as standard of care
Study NCT03213353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tablet paracetamol, guaifenesin and phenylephrine HCL
Description: Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
Study NCT02928939 — intervention group
Intervention type: OTHER
Intervention: drug-drug or drug-disease interaction
Study NCT03213353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicks Active SymptoMax Plus powder for oral solution
Description: Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
Study NCT01107418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage b) orally twice daily, days 1-15 (morning dose)
Study NCT01107418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage c) orally twice daily, days 1-15 (morning dose)
Study NCT03661970 — intervention group
Intervention type: OTHER
Intervention: Cognate Speech Synthesizer sound percepts
Description: The cognate speech synthesizer will generate an acoustic output, as well as a visual display of the acoustic signals. The outputs on the monitor and the synthesizer will be recorded.
Study NCT01107418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage d) orally twice daily, days 1-15 (morning dose)
Study NCT03031639 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic approach thyroidectomy
Description: Thyroid surgery using endoscopy.
Study NCT01425762 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug Dose
Description: 100 versus 200 mcg IT morphine
Study NCT01425762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug Dose
Description: 100 versus 200 mcg IT morphine
Study NCT01107418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg orally twice daily, from day 22 onward
Study NCT04635878 — intervention group
Intervention type: OTHER
Intervention: Blood collection
Description: Blood collection (at admission, two days, one week and at discharge) to analyze the activation of NLRP3 inflammasome in platelets and leukocytes
Study NCT02358590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPA menu-based mini-video
Description: The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
Study NCT02358590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The treating physician will advice participants to take vitamin D
Study NCT03715374 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periodontal Surgery with PRF+ABB
Description: Patients will be treated by periodontal surgical flaps with the addition of PRF+ Anorganic Bovine Bone filling material
Study NCT03715374 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal Surgery with Collagen Membrane +ABB
Description: Patients will be treated by periodontal surgical flaps with the addition of Collagen Membrane + Anorganic Bovine Bone filling material
Study NCT04318080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg intravenously (IV) every 3 weeks (Q3W)
Study NCT04995562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129Xe
Description: Inhaled contrast for MRI
Study NCT04129580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSET-O app
Description: The reSET-O app, owned by Pear Therapeutics, Inc., is designed to work as cognitive behavioral therapy, adjunctive to medication assisted treatment, for opioid use disorder. The app provides psychoeducation related to opioid use and dependence, coping skills, and skills to avoid relapse,
Study NCT01107418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: dosage a) orally twice daily, days 1-15 (morning dose)
Study NCT00597701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
Study NCT00682825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bispectral index protocol
Description: Aim to titrate anesthesia to maintain BIS between 40 and 60.
Study NCT00682825 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: End tidal anesthetic gas-guided
Description: Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
Study NCT03175744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellarex DCB
Description: Intervention with the Stellarex DCB
Study NCT03175744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTA Catheter
Description: Intervention with an uncoated Standard PTA
Study NCT04562064 — intervention group
Intervention type: DEVICE
Intervention: corneal tomography scans
Description: corneal tomography scans of the two corneal surfaces were obtained preoperatively and postoperatively with a rotating Scheimpflug imaging system
Study NCT00440128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel
Study NCT00440128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casopitant/Docetaxel
Description: Casopitant/Docetaxel
Study NCT01911182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhalation of low concentration of CO2
Description: Inhalation of 1% CO2 through nasal prongs
Study NCT02419911 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: FloShield Defogging and Cleaning System
Description: Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
Study NCT02419911 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clearify Defogging and Cleaning System
Description: Single-use, ex vivo device to clean and defog the laparoscope camera lens
Study NCT01911182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of low concentration of CO2
Description: Inhalation of 1% CO2 through nasal prongs
Study NCT01033669 — intervention group
Intervention type: DEVICE
Intervention: CRC-749
Description: There is no drug being used. This is a device.
Study NCT01033669 — intervention group
Intervention type: DEVICE
Intervention: Diskus
Description: There is no drug being used. This is a device.
Study NCT01033669 — intervention group
Intervention type: DEVICE
Intervention: Twisthaler
Description: There is no drug being used. This is a device.
Study NCT02213198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement focused care
Description: Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
Study NCT02213198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
Study NCT01033669 — intervention group
Intervention type: DEVICE
Intervention: Miat Monohaler
Description: There is no drug being used. This is a device.
Study NCT04498273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 2.5 MG
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 2.5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study NCT04498273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban 5MG
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Apixaban 5 MG twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study NCT00597701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00597701 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms.
Study NCT00597701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms.
Study NCT04498273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study drug will be shipped to subjects home. Subjects will take Aspirin twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study NCT01637051 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock
Description: A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert.
Study NCT01637051 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer NexGen® Trabecular Metal Technology (TMT), Modular
Description: A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).~The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert.
Study NCT03344731 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive evaluation
Description: Cognitive task
Study NCT04498273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study NCT04774562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Assisted Discharge Education (VADE)
Description: Video-Assisted Discharge Education (VADE): Information about THR, preventive rehabilitation approaches, transfer activities, using stairs, self-care activities.